| Name | Year | Target | 1st approval indication | Mechanism of action |
| Denosumab | 2010 | RANKL | Bone metastasis | Signal Inhibition |
| Ipilimumab | 2011 | CTLA-4 | Metastatic melanoma | Signal inhibition |
| Brenfuximab (vedotin) | 2011 | CD30 | Hodgkin’s lymphoma | ADC |
| Pertuzumab | 2012 | HER2 | Breast cancer | Signal inhibition, ADCC |
| Trastuzumab (ematansine) | 2013 | HER2 | Breast cancer | Signal inhibition, ADCC |